Trials / Withdrawn
WithdrawnNCT04821219
Personalized Management of Pancreatic Adenocarcinoma Using Patient-Derived Tumoroids
Establishing a Platform for Personalized Approach to the Management of Pancreatic Adenocarcinoma Using Patient-Derived Tumoroids
- Status
- Withdrawn
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to prospectively investigate the feasibility of establishing patient-derived tumoroids (PDT) as a platform for a personalized approach for response prediction and guide optimal neoadjuvant and/or adjuvant approach. PDT will be investigated to determine drug sensitivity, predict the response to chemotherapy agents and radiation therapy, and validate this response in treated patients, and to establish the feasibility of PDT as a platform for a personalized approach to guide multimodality treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Treatment prediction PDT platform | PDT will be generated and response to various chemotherapies and radiation will be investigated. Actionable targets will be identified and response to the target drug will be assessed and compared to the conventional treatment options. |
Timeline
- Start date
- 2022-01-01
- Primary completion
- 2023-12-31
- Completion
- 2023-12-31
- First posted
- 2021-03-29
- Last updated
- 2022-02-24
Source: ClinicalTrials.gov record NCT04821219. Inclusion in this directory is not an endorsement.